The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Importance A randomized clinical trial is needed to determine whether the second-
generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation …

PURPOSE Despite contemporary treatment, up to 10% of children with acute lymphoblastic
leukemia still experience relapse. We evaluated whether a higher dosage of PEG …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) are
recognized as a unique population with specific characteristics and needs. In adolescents …

Advancement in the diagnosis and treatment of pedi-atric acute lymphoblastic leukemia
(ALL) is one of the greatest successes of modern medicine. Over the past 50 years, there …

Acute lymphoblastic leukemia (ALL) is a constellation of diseases driven by genetic
alterations commonly derived from structural chromosome rearrangements, aneuploidy and …

Purpose Dasatinib is a second-generation tyrosine kinase inhibitor with higher central
nervous system (CNS) penetration compared with imatinib and nilotinib in in vitro studies …